Analyst Comments on Gilead Sciences (GILD) P-II TAF Study

Article Related Press Releases (1) Related Articles (1) Stock Quotes (1) Comments (0)

This morning Gilead Sciences, Inc. (Nasdaq: GILD) announced detailed 24-week results from a Phase 2 study (Study 102) evaluating a once-daily single tablet regimen containing tenofovir alafenamide (TAF) for the treatment of HIV-1 infection.

Commenting on the results, analyst at Wells Fargo said, "The detailed data clearly support the potential for TAF's bone and kidney advantages that could address the some of the shortcomings of Viread and make it a successful life cycle strategy, with very similar efficacy and a generally similar safety profile which will need to be confirmed in ph.III."

Wells Fargo has an Outperform rating on Gilead Sciences.

For an analyst ratings summary and ratings history on Gilead Sciences (Nasdaq: GILD) click here. For more ratings news on Gilead Sciences click here.

Shares of Gilead Sciences closed at $43.87 yesterday, with a 52 week range of $39.21-$79.37.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UBS Survey Shows Signs of Strength for Gilead's (GILD) TAF
• Supernus (SUPN) PT Trimmed at Jefferies, But Survey Shows Significant Market Opportunity
• Wells Fargo Upgrades Rosetta Resources (ROSE) to Outperform, Shares Attractive

Create E-mail Alert Related Categories

Analyst Comments, FDA

Related Entities

Wells Fargo

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?